Key Takeaways
- • Wall Street's largest hedge funds—Bridgewater Associates, Tiger Global Management, and Discovery Capital—significantly increased Big Tech exposure in Q2 2025, reversing earlier-year pullbacks driven by tariff volatility and AI bubble concerns.
- • Bridgewater more than doubled its Nvidia holdings to $1.14 billion and expanded stakes in Alphabet, Microsoft, Broadcom, and Palo Alto Networks, reflecting concentrated bets on AI-driven earnings growth narratives.
- • Hedge funds simultaneously reduced exposure to underperforming sectors including aerospace and defense, consumer, and retail, repositioning toward momentum-driven technology plays as the S&P 500 gained 10% year-to-date, with large-cap tech stocks accounting for nearly one-third of the index's market capitalization.
- • Beyond pure-play tech, select funds including Lone Pine, Discovery Capital, Berkshire Hathaway, and Soros Fund Management increased positions in UnitedHealth Group despite a 46% year-to-date share decline, citing potential value opportunities amid ongoing DOJ probes, cyberattacks, and operational headwinds.
- • The strategic shift reflects a return to momentum investing after early-2025 sentiment deteriorated around inflation concerns and perceived AI valuation excess, with Q2 2025 13-F filings documenting the largest institutional pivot back to Big Tech since the generational AI boom accelerated.
Summary
Wall Street's mega-cap hedge fund managers executed a dramatic reallocation toward Big Tech during the second quarter of 2025, reversing a significant bearish stance established earlier in the year. Bridgewater Associates, Tiger Global Management, and Discovery Capital—three of the largest systematic and discretionary allocators on the Street—substantially increased their exposure to artificial intelligence-adjacent technology stocks as market sentiment shifted decisively away from tariff-driven volatility and inflation concerns that had triggered broad "Magnificent Seven" sell-offs in the first quarter.
Bridgewater's moves were particularly aggressive. The macro fund more than doubled its Nvidia holdings to $1.14 billion while simultaneously building or expanding positions across a diversified set of AI-enabled infrastructure and software names, including Alphabet, Microsoft, Broadcom, and Palo Alto Networks. This concentrated positioning reflects a thesis that large-cap technology's earnings-growth narrative—underpinned by genuine AI revenue acceleration—has now overcome prior valuation skepticism. The S&P 500's 10% year-to-date gain through Q2 was driven almost entirely by the largest tech companies, which now represent nearly one-third of the broader index's combined market capitalization, creating both opportunity and concentration risk that sophisticated allocators were keen to exploit.
Concurrent with the Big Tech reallocation, hedge funds materially reduced exposure to previously favored but underperforming sectors. Aerospace and defense, consumer, and retail all saw reduced hedge fund positioning during the quarter, signaling a wholesale abandonment of value and dividend-oriented strategies in favor of pure momentum and growth acceleration bets. This marks a stark reversal from early 2025, when monetary tightening concerns and fears of an AI valuation bubble had made technology stocks temporarily toxic for large allocators.
Beyond concentrated technology plays, a notable secondary thesis emerged around UnitedHealth Group, a financially distressed healthcare insurer down 46% year-to-date. Hedge funds including Lone Pine Capital and Discovery Capital, alongside longer-term allocators Berkshire Hathaway and Michael Burry's Scion Asset Management, added positions or initiated stakes in the insurer, while Soros Fund Management boosted an existing position. This contrarian move suggests some sophisticated capital is betting on mean reversion despite UnitedHealth facing a convergence of structural headwinds: rising medical costs, an active U.S. Department of Justice antitrust probe, a significant 2024 cyberattack, and reputational damage from the December 2024 shooting death of former chief executive Brian Thompson. The positions reflect either deep value conviction or a calculation that regulatory and operational risks are overpriced into current valuations.
These Q2 2025 positioning shifts, revealed through mandatory 13-F filings, underscore a broad institutional consensus that the generational AI opportunity cycle has substantively moved past early skepticism and now commands genuine conviction from the largest pools of hedge fund capital. The return to Big Tech concentration and away from defensive sectors signals confidence that earnings growth—not multiple expansion alone—will drive technology stock performance through the remainder of 2025.
Bridgewater's moves were particularly aggressive. The macro fund more than doubled its Nvidia holdings to $1.14 billion while simultaneously building or expanding positions across a diversified set of AI-enabled infrastructure and software names, including Alphabet, Microsoft, Broadcom, and Palo Alto Networks. This concentrated positioning reflects a thesis that large-cap technology's earnings-growth narrative—underpinned by genuine AI revenue acceleration—has now overcome prior valuation skepticism. The S&P 500's 10% year-to-date gain through Q2 was driven almost entirely by the largest tech companies, which now represent nearly one-third of the broader index's combined market capitalization, creating both opportunity and concentration risk that sophisticated allocators were keen to exploit.
Concurrent with the Big Tech reallocation, hedge funds materially reduced exposure to previously favored but underperforming sectors. Aerospace and defense, consumer, and retail all saw reduced hedge fund positioning during the quarter, signaling a wholesale abandonment of value and dividend-oriented strategies in favor of pure momentum and growth acceleration bets. This marks a stark reversal from early 2025, when monetary tightening concerns and fears of an AI valuation bubble had made technology stocks temporarily toxic for large allocators.
Beyond concentrated technology plays, a notable secondary thesis emerged around UnitedHealth Group, a financially distressed healthcare insurer down 46% year-to-date. Hedge funds including Lone Pine Capital and Discovery Capital, alongside longer-term allocators Berkshire Hathaway and Michael Burry's Scion Asset Management, added positions or initiated stakes in the insurer, while Soros Fund Management boosted an existing position. This contrarian move suggests some sophisticated capital is betting on mean reversion despite UnitedHealth facing a convergence of structural headwinds: rising medical costs, an active U.S. Department of Justice antitrust probe, a significant 2024 cyberattack, and reputational damage from the December 2024 shooting death of former chief executive Brian Thompson. The positions reflect either deep value conviction or a calculation that regulatory and operational risks are overpriced into current valuations.
These Q2 2025 positioning shifts, revealed through mandatory 13-F filings, underscore a broad institutional consensus that the generational AI opportunity cycle has substantively moved past early skepticism and now commands genuine conviction from the largest pools of hedge fund capital. The return to Big Tech concentration and away from defensive sectors signals confidence that earnings growth—not multiple expansion alone—will drive technology stock performance through the remainder of 2025.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.